$MNOV

MediciNova (MNOV) reported Phase 2 trial results for MN-001 in treating nonalcoholic fatty liver disease and hypertriglyceridemia. While primary endpoints were not met, significant improvements in HDL-C and HDL-P were observed. MN-001 was well-tolerated. The company plans further analysis and will assess next steps. Additionally, MediciNova is on track to report topline results for its Phase 2b/3 trial of MN-166 in ALS by year-end.

3D Investment Partners Pte. Ltd. sold 640,000 indirectly-held shares of MEDICINOVA INC (MNOV) at $2.70 ($1.73M total) on 2026-09-25. Filed jointly with 3D Opportunity Master Fund.

MEDICINOVA INC (MNOV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026, MediciNova, Inc. (the “Company”) amended its Lease (the “Lease”), dated July 20, 2021, between the Company and the Irvine Company LLC pursuant to a First Amendment to the Lease, dated as of September 23,

MediciNova Inc (MNOV) shares dropped 14.7% premarket after mixed Phase 2 trial results for tipelukast (MN-001) in treating NAFLD and hypertriglyceridemia. While the drug showed improvements in HDL cholesterol and particle concentration, key metrics like triglyceride reduction and liver fat changes were not statistically significant. The company plans further analysis and future study assessments.

Arcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.

MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.

MEDICINOVA INC (MNOV) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Standby Equity Purchase Agreement On August 31, 2026, MediciNova, Inc. (the “Company”) delivered to YA II PN, LTD. (“Yorkville”), a Notice of Termination, informing Yorkville of the Company’s election to ter

MEDICINOVA INC (MNOV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 17, 2026, MediciNova, Inc. (the “Company”) entered into new Executive Employment Agreements (collectively, the “A

MediciNova (NASDAQ: MNOV) said it reached enrollment of 200 patients in the NIH-funded SEANOBI-ALS expanded-access study (NCT 06743776) evaluating MN-166 (ibudilast) in ALS. The program is for patients not eligible for randomized trials. Final follow-ups are expected to finish in early 2027 for data analysis and presentations.

MEDICINOVA INC (MNOV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001226616 false 0001226616 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23,